Isolation and Characterization of a Novel Myophage Abp9 Against Pandrug Resistant .

has emerged as one of the most troublesome pathogens in health care institutions. can cause a wide range of diseases in humans, including pneumonia and septicemia. Phage therapy has drawn great interest from medical researchers as a potential way to control infections by antibiotic-resistant . Using a pandrug-resistant clinical isolate AB9 as an indicator, we isolated a lytic phage Abp9 from hospital sewage. Abp9 belongs to family and shows a wider host range of 12%. Abp9 contains a linear double-stranded DNA genome of 44,820 bp with a G + C content of 37.69%. The Abp9 genome contains 80 open reading frames, but lacks any known virulence genes or lysogen-formation genes. In a systemic infection mouse models, Abp9 treatment showed good therapeutic effects. We have also observed an excellent lytic activity against in biofilm form of growth . All of these suggest that Abp9 is a good candidate for the phage therapy against drug-resistant infections.